Recent headlines about a potent new immunotherapy have mostly focused on the U.S. company helping to develop it. Less attention has been paid to Akeso, a Chinese biotech that had kept a low profile until its drug bested Merck’s mega-blockbuster Keytruda in a late-stage lung cancer trial.
Now, Akeso’s leaders want you to know that its recent success isn’t a one-off.
“We have a deep pipeline that goes beyond ivonescimab,” Bing Wang, Akeso’s chief financial officer, told STAT. “And we definitely want to position Akeso as a global biotech, not just a China story.”
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in